陕西方舟制药

Shaanxi Fangzhou Pharmaceutical is a Chinese pharmaceutical company specializing in the research, development, and manufacturing of both chemical drugs and Traditional Chinese Medicine (TCM). Founded in 1998 and headquartered in Xi'an, the company focuses on therapeutic areas such as cardiovascular and cerebrovascular diseases, urology, and oncology. Its product portfolio includes well-known generics like Amlodipine Besylate and Donepezil Hydrochloride, as well as proprietary TCM formulations for prostate health. The company operates modern manufacturing facilities that comply with national GMP standards, ensuring high-quality production of tablets, capsules, and granules. In 2014, the company was acquired by the publicly traded Guangxi Zhongheng Group, integrating it into a larger healthcare conglomerate. Shaanxi Fangzhou continues to be a significant player in the regional pharmaceutical market, emphasizing the modernization of traditional therapies.